Wonbiogen launches 6 dermatological skincare products exclusive to E-Mart's PB brand Nobland
Predicted impact: Low
Wonbiogen원바이오젠
307280 · KOSDAQ · ₩307280 · 원바이오젠
₩5,500▼ ₩120 (2.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y +10.00%
- Market cap
- ₩39B
- Enterprise value
- ₩32B
- P/E
- 4.6×
- P/B
- 0.9×
- Dividend yield
- 2.5%
- ROE
- 18.8%
- Net margin
- 22.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−34.5% from the high
₩4,765Today: ₩5,350 – ₩5,680₩8,400
Returns
- 1W−3.0%
- 1M−8.2%
- 3M+3.0%
- 6M−26.0%
- YTD−17.7%
- 1Y+10.0%
- Volume today
- 18,837
- 1.6× the 20-day average
- Traded today
- ₩103M
- Listed shares
- 7,094,627
- EPS (12 months)
- ₩1,187
- Earnings yield 21.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 53 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A new retail partnership for skincare products is a positive development. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-6.8% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Wonbiogen stock overview
Wonbiogen (원바이오젠, KRX: 307280) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures wound dressings, mainly foam dressings and hydrocolloid dressings, and supplies them to domestic pharmaceutical companies on an ODM basis and sells them under its own brand through distributors. Its shares closed at ₩5,500 on Oct 30, 2026, down 2.14% on the day, giving it a market value of ₩39B.
Key facts
- Market cap
- ₩39B
- Sector
- Biotech & Pharma
- Latest price change
- −2.14%
- As of
- Oct 30, 2026
- Main business
- The company manufactures wound dressings, mainly foam dressings and hydrocolloid dressings, and supplies them to domestic pharmaceutical companies on an ODM basis and sells them under its own brand through distributors.
Quick answers about Wonbiogen
- What does Wonbiogen do?
- The company manufactures wound dressings, mainly foam dressings and hydrocolloid dressings, and supplies them to domestic pharmaceutical companies on an ODM basis and sells them under its own brand through distributors. Its main markets are hospitals (ETC) and pharmacies and general distribution (OTC). The excerpt also covers the market trends for wound dressings and dermacosmetics in Korea and globally.
- What is the market cap of Wonbiogen?
- The market capitalisation of Wonbiogen was ₩39B at the close on Oct 30, 2026.
- When is the next earnings report from Wonbiogen?
- Korean companies rarely announce results dates in advance. Based on when Wonbiogen filed the same report in past years, its next 3q results is expected between Nov 8, 2026 and Nov 13, 2026.
Company profile
The company manufactures wound dressings, mainly foam dressings and hydrocolloid dressings, and supplies them to domestic pharmaceutical companies on an ODM basis and sells them under its own brand through distributors. Its main markets are hospitals (ETC) and pharmacies and general distribution (OTC). The excerpt also covers the market trends for wound dressings and dermacosmetics in Korea and globally.
Written by AI from the company's latest annual report.
- Korean name
- 원바이오젠
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김원일
- Founded
- Sep 2018
- Listed
- Dec 2018
- Listed shares
- 7,094,627
- Fiscal year ends
- Month 12
- Website
- wonbiogen.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
Wonbiogen Co-Develops 'Dermatology-Based Cleanser' with Korean Society of Skin Functional Medicine
Predicted impact: Low
Cleanser co-development with a medical society is a small product item with limited financial impact.
Wonbiogen Completes ₩13B Facility to Expand Wound Dressing and Cosmetics Production
Predicted impact: Low
Recent filings
See all- Amended: Half-year report (Jun 2026)Oct 2, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- [Amended] New Facility Investment, etc. (Voluntary Disclosure)Jul 31, 2026
- [Amended] New Facility Investment, etc. (Voluntary Disclosure)Jun 30, 2026
- Trust Contract Termination Result ReportJun 9, 2026
Titles in Korean until English translations are added.
Also known as: Wonbiogen / 원바이오젠 / 307280 / KRX:307280
Source: KRX statistical information